Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Glioblastoma 12Prostatic Neoplasms 11Breast Neoplasms 10Lung Neoplasms 9Carcinoma, Non-Small-Cell Lung 9Neoplasm Metastasis 7Squamous Cell Carcinoma of Head and Neck 6Sarcoma 5Oropharyngeal Neoplasms 5Neoplasms 4Histiocytoma, Malignant Fibrous 4Head and Neck Neoplasms 4Brain Neoplasms 4Astrocytoma 4Uterine Cervical Neoplasms 3Urinary Bladder Neoplasms 3Triple Negative Breast Neoplasms 3Sarcoma, Synovial 3Rhabdomyosarcoma 3Melanoma 3Liposarcoma 3Leiomyosarcoma 3Hodgkin Disease 3Esophageal Squamous Cell Carcinoma 3Carcinoma, Hepatocellular 3Adenocarcinoma Of Esophagus 3Stomach Neoplasms 2Sarcoma, Ewing 2Rhabdomyosarcoma, Embryonal 2Rhabdomyosarcoma, Alveolar 2

Interventions

Gemcitabine 6Cisplatin 6Magnetic Resonance Spectroscopy 5Specimen Handling 4Capecitabine 4Biopsy 3pembrolizumab 2durvalumab 2Trastuzumab 2Platinum 2Oxaliplatin 2Leucovorin 2Fluorouracil 21,2-diaminocyclohexaneplatinum II citrate 2varlilumab 1tucatinib 1toripalimab 1peposertib 1guadecitabine 1dehydroftorafur 1cobimetinib 1binimetinib 1avelumab 1atezolizumab 1Tegafur 1Taxes 1S 1 (combination) 1Radiotherapy, Intensity-Modulated 1Radiation Dose Hypofractionation 1Radiation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Gallbladder Neoplasms × Radiation × Clear all
NCT04068194 2026-05-13

Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
103 enrolled
Gastrointestinal

Gallbladder Neoplasms, Neoplasm Metastasis, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡